Anti-GDF15 Antibodies Reversing Cachexia via C-Terminal Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cachexia, particularly in cancer patients, are often ineffective and only addressed in advanced stages of the disease, leading to significant morbidity and mortality, with a need for improved therapeutic agents targeting Growth Differentiation Factor 15 (GDF15) given its role in anorexia and weight loss.
Innovation Solution
Development of high-affinity and specific anti-GDF15 antibodies that bind to the C-terminal region of GDF15, inhibiting its anorexigenic effects and weight loss-promoting actions, which can be used alone or in combination with other therapies to treat cachexia-associated disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments for cachexia are used, then patient quality of life may be maintained temporarily, but treatment effectiveness is poor and only addresses advanced stages leading to high morbidity and mortality
Solution Approach 1:
The patent applies preliminary action by developing anti-GDF15 antibodies that can intervene in the cachexia pathway before severe weight loss and muscle wasting occur. The antibodies target GDF15 early in the disease process, preventing the progression to advanced cachexia stages rather than treating only when severe symptoms are present.
Solution Approach 2:
The patent uses anti-GDF15 antibodies as intermediary molecules that bind to GDF15 and block its interaction with receptors, thereby mediating the prevention of cachexia. The antibodies serve as a bridge that intercepts the harmful GDF15 signal before it can exert its catabolic effects on muscle and fat tissue.
2Reliability
If GDF15 levels are elevated to suppress tumor growth, then anti-tumor efficacy is improved, but anorexia and weight loss are exacerbated
Solution Approach 1:
The patent applies local quality by creating antibodies with specific affinity and specificity for GDF15 that can selectively block GDF15's harmful effects on appetite and metabolism while potentially allowing other GDF15 functions to proceed. The antibodies are engineered to bind specifically to certain epitopes on GDF15, achieving selective inhibition of unwanted effects.
Solution Approach 2:
The patent applies partial action by using anti-GDF15 antibodies that partially neutralize GDF15 activity rather than completely eliminating it. This partial inhibition allows sufficient GDF15 function to maintain anti-tumor effects while blocking enough activity to prevent severe anorexia and weight loss, achieving a therapeutic balance.
3Measurement precision
If high-affinity anti-GDF15 antibodies are developed, then binding specificity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies parameter changes by optimizing various parameters of the antibody molecules including affinity, specificity, isotype, and structural characteristics to achieve high binding precision. The antibodies are engineered with specific variable region sequences and CDR regions that confer high affinity for GDF15 while maintaining manufacturability through standardized constant regions and humanized frameworks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-GDF15 antibodies effectively increase food intake and body weight, reversing GDF15-mediated anorexia and weight loss, providing a potential therapeutic option for cachexia and related wasting disorders.
Implementation Method 1
anti-GDF15 antibodies that bind to the C-terminal region of GDF15, inhibiting its anorexigenic effects
Data Source
AI summary
Provided herein are monoclonal antibodies (e.g., human antibodies) binding to human Growth Differentiation Factor 15 protein (hereinafter, sometimes referred to as “GDF15”), and pharmaceutical compositions and methods of treatment comprising the same.